ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Poxviridae Infections Drug Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-17X9985
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Poxviridae Infections Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Poxviridae Infections Drug Market Research Report 2025

Code: QYRE-Auto-17X9985
Report
January 2025
Pages:96
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bavarian Nordic A S
BioFactura
CEL-SCI Corporation
Chimerix
China Biologic Products, Inc.
CJ HealthCare Corp
EpiVax
N& N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.

Poxviridae Infections Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Poxviridae Infections Drug Market

Poxviridae Infections Drug Market

The global market for Poxviridae Infections Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Poxviridae Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Poxviridae Infections Drug.
The Poxviridae Infections Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Poxviridae Infections Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Poxviridae Infections Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Poxviridae Infections Drug Market Report

Report Metric Details
Report Name Poxviridae Infections Drug Market
CAGR 5%
Segment by Type
  • CJ-40011
  • 24a
  • BA-368
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bavarian Nordic A/S, BioFactura, Inc., CEL-SCI Corporation, Chimerix, Inc., China Biologic Products, Inc., CJ HealthCare Corp., EpiVax, Inc., N & N Pharmaceuticals Inc., SIGA Technologies, Inc., Takeda Pharmaceutical Company Limited, Tonix Pharmaceuticals Holding Corp., Verrica Pharmaceuticals Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Poxviridae Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Poxviridae Infections Drug Market report?

Ans: The main players in the Poxviridae Infections Drug Market are Bavarian Nordic A/S, BioFactura, Inc., CEL-SCI Corporation, Chimerix, Inc., China Biologic Products, Inc., CJ HealthCare Corp., EpiVax, Inc., N & N Pharmaceuticals Inc., SIGA Technologies, Inc., Takeda Pharmaceutical Company Limited, Tonix Pharmaceuticals Holding Corp., Verrica Pharmaceuticals Inc.

What are the Application segmentation covered in the Poxviridae Infections Drug Market report?

Ans: The Applications covered in the Poxviridae Infections Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Poxviridae Infections Drug Market report?

Ans: The Types covered in the Poxviridae Infections Drug Market report are CJ-40011, 24a, BA-368, Others

Recommended Reports

Viral Infection Drugs

Infectious Disease Vaccines

Diagnostics & Monitoring

1 Poxviridae Infections Drug Market Overview
1.1 Product Definition
1.2 Poxviridae Infections Drug by Type
1.2.1 Global Poxviridae Infections Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 CJ-40011
1.2.3 24a
1.2.4 BA-368
1.2.5 Others
1.3 Poxviridae Infections Drug by Application
1.3.1 Global Poxviridae Infections Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Poxviridae Infections Drug Market Size Estimates and Forecasts
1.4.1 Global Poxviridae Infections Drug Revenue 2020-2031
1.4.2 Global Poxviridae Infections Drug Sales 2020-2031
1.4.3 Global Poxviridae Infections Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Poxviridae Infections Drug Market Competition by Manufacturers
2.1 Global Poxviridae Infections Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Poxviridae Infections Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Poxviridae Infections Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Poxviridae Infections Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Poxviridae Infections Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Poxviridae Infections Drug, Product Type & Application
2.7 Global Key Manufacturers of Poxviridae Infections Drug, Date of Enter into This Industry
2.8 Global Poxviridae Infections Drug Market Competitive Situation and Trends
2.8.1 Global Poxviridae Infections Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Poxviridae Infections Drug Players Market Share by Revenue
2.8.3 Global Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Poxviridae Infections Drug Market Scenario by Region
3.1 Global Poxviridae Infections Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Poxviridae Infections Drug Sales by Region: 2020-2031
3.2.1 Global Poxviridae Infections Drug Sales by Region: 2020-2025
3.2.2 Global Poxviridae Infections Drug Sales by Region: 2026-2031
3.3 Global Poxviridae Infections Drug Revenue by Region: 2020-2031
3.3.1 Global Poxviridae Infections Drug Revenue by Region: 2020-2025
3.3.2 Global Poxviridae Infections Drug Revenue by Region: 2026-2031
3.4 North America Poxviridae Infections Drug Market Facts & Figures by Country
3.4.1 North America Poxviridae Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Poxviridae Infections Drug Sales by Country (2020-2031)
3.4.3 North America Poxviridae Infections Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Poxviridae Infections Drug Market Facts & Figures by Country
3.5.1 Europe Poxviridae Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Poxviridae Infections Drug Sales by Country (2020-2031)
3.5.3 Europe Poxviridae Infections Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Poxviridae Infections Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Poxviridae Infections Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Poxviridae Infections Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Poxviridae Infections Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Poxviridae Infections Drug Market Facts & Figures by Country
3.7.1 Latin America Poxviridae Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Poxviridae Infections Drug Sales by Country (2020-2031)
3.7.3 Latin America Poxviridae Infections Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Poxviridae Infections Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Poxviridae Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Poxviridae Infections Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Poxviridae Infections Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Poxviridae Infections Drug Sales by Type (2020-2031)
4.1.1 Global Poxviridae Infections Drug Sales by Type (2020-2025)
4.1.2 Global Poxviridae Infections Drug Sales by Type (2026-2031)
4.1.3 Global Poxviridae Infections Drug Sales Market Share by Type (2020-2031)
4.2 Global Poxviridae Infections Drug Revenue by Type (2020-2031)
4.2.1 Global Poxviridae Infections Drug Revenue by Type (2020-2025)
4.2.2 Global Poxviridae Infections Drug Revenue by Type (2026-2031)
4.2.3 Global Poxviridae Infections Drug Revenue Market Share by Type (2020-2031)
4.3 Global Poxviridae Infections Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Poxviridae Infections Drug Sales by Application (2020-2031)
5.1.1 Global Poxviridae Infections Drug Sales by Application (2020-2025)
5.1.2 Global Poxviridae Infections Drug Sales by Application (2026-2031)
5.1.3 Global Poxviridae Infections Drug Sales Market Share by Application (2020-2031)
5.2 Global Poxviridae Infections Drug Revenue by Application (2020-2031)
5.2.1 Global Poxviridae Infections Drug Revenue by Application (2020-2025)
5.2.2 Global Poxviridae Infections Drug Revenue by Application (2026-2031)
5.2.3 Global Poxviridae Infections Drug Revenue Market Share by Application (2020-2031)
5.3 Global Poxviridae Infections Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bavarian Nordic A/S
6.1.1 Bavarian Nordic A/S Company Information
6.1.2 Bavarian Nordic A/S Description and Business Overview
6.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio
6.1.5 Bavarian Nordic A/S Recent Developments/Updates
6.2 BioFactura, Inc.
6.2.1 BioFactura, Inc. Company Information
6.2.2 BioFactura, Inc. Description and Business Overview
6.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 BioFactura, Inc. Poxviridae Infections Drug Product Portfolio
6.2.5 BioFactura, Inc. Recent Developments/Updates
6.3 CEL-SCI Corporation
6.3.1 CEL-SCI Corporation Company Information
6.3.2 CEL-SCI Corporation Description and Business Overview
6.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio
6.3.5 CEL-SCI Corporation Recent Developments/Updates
6.4 Chimerix, Inc.
6.4.1 Chimerix, Inc. Company Information
6.4.2 Chimerix, Inc. Description and Business Overview
6.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Chimerix, Inc. Poxviridae Infections Drug Product Portfolio
6.4.5 Chimerix, Inc. Recent Developments/Updates
6.5 China Biologic Products, Inc.
6.5.1 China Biologic Products, Inc. Company Information
6.5.2 China Biologic Products, Inc. Description and Business Overview
6.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio
6.5.5 China Biologic Products, Inc. Recent Developments/Updates
6.6 CJ HealthCare Corp.
6.6.1 CJ HealthCare Corp. Company Information
6.6.2 CJ HealthCare Corp. Description and Business Overview
6.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio
6.6.5 CJ HealthCare Corp. Recent Developments/Updates
6.7 EpiVax, Inc.
6.7.1 EpiVax, Inc. Company Information
6.7.2 EpiVax, Inc. Description and Business Overview
6.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 EpiVax, Inc. Poxviridae Infections Drug Product Portfolio
6.7.5 EpiVax, Inc. Recent Developments/Updates
6.8 N & N Pharmaceuticals Inc.
6.8.1 N & N Pharmaceuticals Inc. Company Information
6.8.2 N & N Pharmaceuticals Inc. Description and Business Overview
6.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
6.8.5 N & N Pharmaceuticals Inc. Recent Developments/Updates
6.9 SIGA Technologies, Inc.
6.9.1 SIGA Technologies, Inc. Company Information
6.9.2 SIGA Technologies, Inc. Description and Business Overview
6.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio
6.9.5 SIGA Technologies, Inc. Recent Developments/Updates
6.10 Takeda Pharmaceutical Company Limited
6.10.1 Takeda Pharmaceutical Company Limited Company Information
6.10.2 Takeda Pharmaceutical Company Limited Description and Business Overview
6.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio
6.10.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
6.11 Tonix Pharmaceuticals Holding Corp.
6.11.1 Tonix Pharmaceuticals Holding Corp. Company Information
6.11.2 Tonix Pharmaceuticals Holding Corp. Description and Business Overview
6.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio
6.11.5 Tonix Pharmaceuticals Holding Corp. Recent Developments/Updates
6.12 Verrica Pharmaceuticals Inc.
6.12.1 Verrica Pharmaceuticals Inc. Company Information
6.12.2 Verrica Pharmaceuticals Inc. Description and Business Overview
6.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
6.12.5 Verrica Pharmaceuticals Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Poxviridae Infections Drug Industry Chain Analysis
7.2 Poxviridae Infections Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Poxviridae Infections Drug Production Mode & Process Analysis
7.4 Poxviridae Infections Drug Sales and Marketing
7.4.1 Poxviridae Infections Drug Sales Channels
7.4.2 Poxviridae Infections Drug Distributors
7.5 Poxviridae Infections Drug Customer Analysis
8 Poxviridae Infections Drug Market Dynamics
8.1 Poxviridae Infections Drug Industry Trends
8.2 Poxviridae Infections Drug Market Drivers
8.3 Poxviridae Infections Drug Market Challenges
8.4 Poxviridae Infections Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bavarian Nordic A S
BioFactura
CEL-SCI Corporation
Chimerix
China Biologic Products, Inc.
CJ HealthCare Corp
EpiVax
N& N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.
List of Tables
 Table 1. Global Poxviridae Infections Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Poxviridae Infections Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Poxviridae Infections Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Poxviridae Infections Drug Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Poxviridae Infections Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Poxviridae Infections Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Poxviridae Infections Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Poxviridae Infections Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Poxviridae Infections Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Poxviridae Infections Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Poxviridae Infections Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Poxviridae Infections Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Poxviridae Infections Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Poxviridae Infections Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Poxviridae Infections Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Poxviridae Infections Drug Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Poxviridae Infections Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Poxviridae Infections Drug Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Poxviridae Infections Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Poxviridae Infections Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Poxviridae Infections Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Poxviridae Infections Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Poxviridae Infections Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Poxviridae Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Poxviridae Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Poxviridae Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Poxviridae Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Poxviridae Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Poxviridae Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Poxviridae Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Poxviridae Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Poxviridae Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Poxviridae Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Poxviridae Infections Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Poxviridae Infections Drug Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Poxviridae Infections Drug Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Poxviridae Infections Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Poxviridae Infections Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Poxviridae Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Poxviridae Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Poxviridae Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Poxviridae Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Poxviridae Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Poxviridae Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Poxviridae Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Poxviridae Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Poxviridae Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Poxviridae Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Poxviridae Infections Drug Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Poxviridae Infections Drug Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Poxviridae Infections Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Poxviridae Infections Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Poxviridae Infections Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Poxviridae Infections Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Poxviridae Infections Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Poxviridae Infections Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Poxviridae Infections Drug Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Poxviridae Infections Drug Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Poxviridae Infections Drug Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Poxviridae Infections Drug Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Poxviridae Infections Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Poxviridae Infections Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Poxviridae Infections Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Poxviridae Infections Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Poxviridae Infections Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Poxviridae Infections Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Poxviridae Infections Drug Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Poxviridae Infections Drug Price (USD/Pcs) by Application (2026-2031)
 Table 70. Bavarian Nordic A/S Company Information
 Table 71. Bavarian Nordic A/S Description and Business Overview
 Table 72. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Bavarian Nordic A/S Poxviridae Infections Drug Product
 Table 74. Bavarian Nordic A/S Recent Developments/Updates
 Table 75. BioFactura, Inc. Company Information
 Table 76. BioFactura, Inc. Description and Business Overview
 Table 77. BioFactura, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. BioFactura, Inc. Poxviridae Infections Drug Product
 Table 79. BioFactura, Inc. Recent Developments/Updates
 Table 80. CEL-SCI Corporation Company Information
 Table 81. CEL-SCI Corporation Description and Business Overview
 Table 82. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. CEL-SCI Corporation Poxviridae Infections Drug Product
 Table 84. CEL-SCI Corporation Recent Developments/Updates
 Table 85. Chimerix, Inc. Company Information
 Table 86. Chimerix, Inc. Description and Business Overview
 Table 87. Chimerix, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Chimerix, Inc. Poxviridae Infections Drug Product
 Table 89. Chimerix, Inc. Recent Developments/Updates
 Table 90. China Biologic Products, Inc. Company Information
 Table 91. China Biologic Products, Inc. Description and Business Overview
 Table 92. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. China Biologic Products, Inc. Poxviridae Infections Drug Product
 Table 94. China Biologic Products, Inc. Recent Developments/Updates
 Table 95. CJ HealthCare Corp. Company Information
 Table 96. CJ HealthCare Corp. Description and Business Overview
 Table 97. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. CJ HealthCare Corp. Poxviridae Infections Drug Product
 Table 99. CJ HealthCare Corp. Recent Developments/Updates
 Table 100. EpiVax, Inc. Company Information
 Table 101. EpiVax, Inc. Description and Business Overview
 Table 102. EpiVax, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. EpiVax, Inc. Poxviridae Infections Drug Product
 Table 104. EpiVax, Inc. Recent Developments/Updates
 Table 105. N & N Pharmaceuticals Inc. Company Information
 Table 106. N & N Pharmaceuticals Inc. Description and Business Overview
 Table 107. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product
 Table 109. N & N Pharmaceuticals Inc. Recent Developments/Updates
 Table 110. SIGA Technologies, Inc. Company Information
 Table 111. SIGA Technologies, Inc. Description and Business Overview
 Table 112. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 113. SIGA Technologies, Inc. Poxviridae Infections Drug Product
 Table 114. SIGA Technologies, Inc. Recent Developments/Updates
 Table 115. Takeda Pharmaceutical Company Limited Company Information
 Table 116. Takeda Pharmaceutical Company Limited Description and Business Overview
 Table 117. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 118. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product
 Table 119. Takeda Pharmaceutical Company Limited Recent Developments/Updates
 Table 120. Tonix Pharmaceuticals Holding Corp. Company Information
 Table 121. Tonix Pharmaceuticals Holding Corp. Description and Business Overview
 Table 122. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 123. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product
 Table 124. Tonix Pharmaceuticals Holding Corp. Recent Developments/Updates
 Table 125. Verrica Pharmaceuticals Inc. Company Information
 Table 126. Verrica Pharmaceuticals Inc. Description and Business Overview
 Table 127. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 128. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product
 Table 129. Verrica Pharmaceuticals Inc. Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Poxviridae Infections Drug Distributors List
 Table 133. Poxviridae Infections Drug Customers List
 Table 134. Poxviridae Infections Drug Market Trends
 Table 135. Poxviridae Infections Drug Market Drivers
 Table 136. Poxviridae Infections Drug Market Challenges
 Table 137. Poxviridae Infections Drug Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Poxviridae Infections Drug
 Figure 2. Global Poxviridae Infections Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Poxviridae Infections Drug Market Share by Type: 2024 & 2031
 Figure 4. CJ-40011 Product Picture
 Figure 5. 24a Product Picture
 Figure 6. BA-368 Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Poxviridae Infections Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Poxviridae Infections Drug Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Others
 Figure 13. Global Poxviridae Infections Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Poxviridae Infections Drug Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Poxviridae Infections Drug Sales (2020-2031) & (K Pcs)
 Figure 16. Global Poxviridae Infections Drug Average Price (USD/Pcs) & (2020-2031)
 Figure 17. Poxviridae Infections Drug Report Years Considered
 Figure 18. Poxviridae Infections Drug Sales Share by Manufacturers in 2024
 Figure 19. Global Poxviridae Infections Drug Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Poxviridae Infections Drug Players: Market Share by Revenue in Poxviridae Infections Drug in 2024
 Figure 21. Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Poxviridae Infections Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Poxviridae Infections Drug Sales Market Share by Country (2020-2031)
 Figure 24. North America Poxviridae Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Poxviridae Infections Drug Sales Market Share by Country (2020-2031)
 Figure 28. Europe Poxviridae Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Poxviridae Infections Drug Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Poxviridae Infections Drug Revenue Market Share by Region (2020-2031)
 Figure 36. China Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Poxviridae Infections Drug Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Poxviridae Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Poxviridae Infections Drug Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Poxviridae Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. U.A.E Poxviridae Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Poxviridae Infections Drug by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Poxviridae Infections Drug by Type (2020-2031)
 Figure 58. Global Poxviridae Infections Drug Price (USD/Pcs) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Poxviridae Infections Drug by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Poxviridae Infections Drug by Application (2020-2031)
 Figure 61. Global Poxviridae Infections Drug Price (USD/Pcs) by Application (2020-2031)
 Figure 62. Poxviridae Infections Drug Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Rhinovirus Infections Drug Market Research Report 2024
Global Viral Vaccines Market Research Report 2025
Global Human Papillomavirus Infection Drug Market Research Report 2025
Global IPV Vaccine Market Research Report 2025
Coxsackievirus Infections Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti Infectives Market Research Report 2025
Global Monkeypox Diagnostic Kit Market Research Report 2024
Virus Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti infectious Disease Drugs Market Research Report 2025
Global West Nile Virus Infections Medicine Market Research Report 2025
Global Vaginitis Therapeutics Market Insights Forecast to 2030
Global Live Attenuated Varicella Vaccine Market Research Report 2025
Global Hepatitis Viruses Diagnostic Tests Market Research Report 2024
Global Herpes Infection Treatment Market Research Report 2025
Infectious Disease Diagnostic Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inactivated Polio Virus Vaccine Market Research Report 2025
Global Ant Killer Market Research Report 2024
Systemic Infection Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Glass Vials Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rotavirus Infections Drug Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions